80 related articles for article (PubMed ID: 26457577)
1. Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review.
Froes Brandao D; Strasser-Weippl K; Goss PE
Cancer; 2016 Jan; 122(2):184-8. PubMed ID: 26457577
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological hyperprolactinemia: a retrospective analysis of 501 hyperprolactinemia cases in primary care setting.
García Cano AM; Rosillo M; Gómez Lozano A; Jiménez Mendiguchía L; Marchán Pinedo M; Rodríguez Torres A; Araujo-Castro M
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3239-3246. PubMed ID: 37910184
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case-Control Database Study.
Solmi M; Lähteenvuo M; Tanskanen A; Corbeil O; Mittendorfer-Rutz E; Correll CU; Tiihonen J; Taipale H
Schizophr Bull; 2024 Apr; ():. PubMed ID: 38687213
[TBL] [Abstract][Full Text] [Related]
4. Relative Risk of Breast Cancer Associated With Prolactin-Increasing Antipsychotic Use.
Taipale H; Solmi M; Correll CU; Tiihonen J
J Clin Psychiatry; 2024 Jan; 85(1):. PubMed ID: 38270548
[No Abstract] [Full Text] [Related]
5. Unusually high prolactin level for medication-induced hyperprolactinemia: a case report.
Akbas EM; Gungor A; Ozdemir C; Bilen H
Eurasian J Med; 2013 Jun; 45(2):138-40. PubMed ID: 25610268
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic treatment, prolactin, and breast tumorigenesis.
De Hert M; Vancampfort D; Stubbs B; Sabbe T; Wildiers H; Detraux J
Psychiatr Danub; 2016 Sep; 28(3):243-254. PubMed ID: 27658833
[TBL] [Abstract][Full Text] [Related]
7. Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia.
Montejo ÁL; Arango C; Bernardo M; Carrasco JL; Crespo-Facorro B; Cruz JJ; Del Pino J; García Escudero MA; García Rizo C; González-Pinto A; Hernández AI; Martín Carrasco M; Mayoral Cleries F; Mayoral van Son J; Mories MT; Pachiarotti I; Ros S; Vieta E
Rev Psiquiatr Salud Ment; 2016; 9(3):158-73. PubMed ID: 26927534
[TBL] [Abstract][Full Text] [Related]
8. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
[TBL] [Abstract][Full Text] [Related]
9. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
Ann Oncol; 2015 Dec; 26(12):2505-6. PubMed ID: 26467471
[No Abstract] [Full Text] [Related]
10. Complete blood counts, liver function tests, and chest x-rays as routine screening in early-stage breast cancer: value added or just cost?
Louie RJ; Tonneson JE; Gowarty M; Goodney PP; Barth RJ; Rosenkranz KM
Breast Cancer Res Treat; 2015 Nov; 154(1):99-103. PubMed ID: 26467045
[TBL] [Abstract][Full Text] [Related]
11. [Prolactin, antipsychotics and breast cancer: is there a connection?].
Sabbe T; Detraux J; De Hert M
Tijdschr Psychiatr; 2016; 58(9):641-9. PubMed ID: 27639886
[TBL] [Abstract][Full Text] [Related]
12. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
13. Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study.
Pottegård A; Lash TL; Cronin-Fenton D; Ahern TP; Damkier P
Br J Clin Pharmacol; 2018 Sep; 84(9):2152-2161. PubMed ID: 29858518
[TBL] [Abstract][Full Text] [Related]
14. Hormonal determinants of mammographic density and density change.
Gabrielson M; Azam S; Hardell E; Holm M; Ubhayasekera KA; Eriksson M; Bäcklund M; Bergquist J; Czene K; Hall P
Breast Cancer Res; 2020 Aug; 22(1):95. PubMed ID: 32847607
[TBL] [Abstract][Full Text] [Related]
15. Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study.
Hicks BM; Busby J; Mills K; O'Neil FA; McIntosh SA; Zhang SD; Liberante FG; Cardwell CR
BMC Cancer; 2020 Aug; 20(1):804. PubMed ID: 32831062
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.
Leehy KA; Truong TH; Mauro LJ; Lange CA
J Steroid Biochem Mol Biol; 2018 Feb; 176():88-93. PubMed ID: 28442393
[TBL] [Abstract][Full Text] [Related]
17. Role of Growth Hormone in Breast Cancer.
Subramani R; Nandy SB; Pedroza DA; Lakshmanaswamy R
Endocrinology; 2017 Jun; 158(6):1543-1555. PubMed ID: 28379395
[TBL] [Abstract][Full Text] [Related]
18. Prolactin receptor in breast cancer: marker for metastatic risk.
Shemanko CS
J Mol Endocrinol; 2016 Nov; 57(4):R153-R165. PubMed ID: 27658959
[TBL] [Abstract][Full Text] [Related]
19. Plasma prolactin and breast cancer risk: a meta- analysis.
Wang M; Wu X; Chai F; Zhang Y; Jiang J
Sci Rep; 2016 May; 6():25998. PubMed ID: 27184120
[TBL] [Abstract][Full Text] [Related]
20. Co-prescription of aripiprazole on prolactin levels in long-term hospitalized chronic schizophrenic patients with co-morbid type 2 diabetes: A retrospective clinical study.
Liu X; Sun X; Li L; Zeng K; Li Y; Gao Y; Ma J
Front Psychiatry; 2023; 14():1124691. PubMed ID: 36816406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
